1032824-92-2

Basic information

• Product Name: (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanol
• Synonyms: (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanol
• CAS NO: 1032824-92-2
• Molecular Weight: 225.291
• Mol File: 1032824-92-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanol(1032824-92-2)
• EPA Substance Registry System: (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanol(1032824-92-2)

Safety Data

• Hazardous Substances Data: 1032824-92-2(Hazardous Substances Data)

Usage

Description

(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanol is a complex organic compound characterized by the presence of a piperidine ring, which is substituted with a 1,2,4-oxadiazol-5-yl group at the 3-position and an isopropyl group at the 1-position. Additionally, a methanol group is attached to the piperidine ring, contributing to the compound's unique structure and potential properties.

Uses

Used in Pharmaceutical Industry:
(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanol is used as a potential pharmaceutical agent due to its structural features that are common in compounds with a wide range of biological activities. The presence of the piperidine ring, which is a core component in many drugs, suggests that this compound may exhibit properties beneficial for the development of medications with antipsychotic, analgesic, and antihistaminic effects.
Further research and testing are required to explore the specific properties and potential applications of (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanol, as its exact uses and efficacy will depend on the outcomes of such studies.

Upstream product

• 6457-49-4 4-piperidinemethanol 
• 506-68-3 bromocyane 
• 22779-89-1 isobutyrohydroxamic acid 

Downstream Products

• 1032823-75-8 ((5-[({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl)oxy]-2-[4-(methylsulfonyl)phenyl]pyridine)) 
• 1351345-55-5 [(3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351338-59-4 (3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-ylamine p-toluenesulfonate 
• 1351345-54-4 ((3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351338-57-2 (3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}pyrrolidin-3-ylamine p-toluenesulfonate 
• 1351345-53-3 ((3R,4S)-4-(4-chloro-2-fluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351338-52-7 ((3R,4S)-4-(4-chloro-2-fluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}pyrrolidin-3-yl)amine 
• 1351345-52-2 [(3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351338-51-6 (3R,4S)-1-{5-[l-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-ylamine 
• 1351345-51-1 ((3R,4S)-4-(2,4-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351345-80-6 C₃₁H₄₀F₂N₆O₄ 
• 1351343-45-7 ((3R,4S)-4-(2,5-difluoro-phenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methoxy-pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351341-81-5 [(3R,4S)-4-(2,5-difluorophenyl)-1-(5-{[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethyl]amino}pyrimidin-2-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351343-05-9 5-bromo-2-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]nicotinonitrile 

Relevant articles and documents

CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.